Analyze Diet
Equine veterinary education2019; 32(Suppl 11); 33-36; doi: 10.1111/eve.13175

Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination.

Abstract: Equine coronavirus (ECoV) is considered an emerging enteric virus with reported morbidity rates ranging from 10 to 83% and fatality rates ranging from 7 to 27% in adult horses; a vaccine for ECoV is currently not available. This study investigated the safety, humoral response and viral shedding in horses inoculated with a commercially available modified-live bovine coronavirus (BCoV) vaccine. Twelve healthy adult horses were vaccinated twice, 3 weeks apart, either orally, intranasally or intrarectally. Two healthy unvaccinated horses served as sentinel controls. Following each vaccine administration, horses were monitored daily for physical abnormalities whilst the onset and duration of BCoV shedding was determined by quantitative PCR (qPCR) in nasal secretions and faeces. Whole blood was collected every 3 weeks to determine BCoV-specific antibody response. With the exception of transient and self-limiting changes in faecal character observed in seven vaccinated and one control horse, no additional abnormal clinical findings were found in the study horses. Following the first and second vaccine administration, two and one horse, respectively, tested qPCR-positive for BCoV in nasal secretions 1-day post intranasal vaccination. No vaccinated horses tested qPCR-positive for BCoV in faeces following each vaccine administration. One of the two horses that shed BCoV seroconverted to BCoV after the first vaccine administration and an additional two vaccinated horses (oral and intrarectal) seroconverted to BCoV after the second vaccine administration. In conclusion, the results show that the modified-live BCoV is safe to administer to horses via various routes, causes minimal virus shedding and results in detectable antibodies to BCoV in 27% of the vaccinates.
Publication Date: 2019-08-31 PubMed ID: 32427191PubMed Central: PMC7228322DOI: 10.1111/eve.13175Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research evaluates the use of a modified live bovine coronavirus vaccine in adult horses and its effects on safety, immune response, and shedding of the virus. The test shows the vaccine is safe to administer, produces minimal virus shedding, and resulted in observable antibodies to bovine coronavirus in over one-fourth of the horses.

Methodology of the Study

  • The study utilized twelve healthy adult horses, which were divided and given two doses of the vaccine in three different manners: orally, intranasally or intrarectally. Each dose was administered three weeks apart.
  • Two additional horses, not given the vaccine acted as control subjects.
  • Post-administration, horses were observed daily for any physical irregularities. The start and duration of BCoV shedding were tested via qPCR in nasal secretions and faeces.
  • Every three weeks, blood samples were collected to measure BCoV-specific antibody response.

Findings of the Study

  • There were no significant adverse clinical findings in the horses given the vaccine, with the exception of temporary changes in faecal character noticed in seven vaccinated horses and one control horse.
  • Post the first and second vaccine administration, some horses tested qPCR-positive for BCoV in nasal secretions, likely indicating temporary shedding of the live-virus.
  • None of the vaccinated horses tested qPCR-positive for BCoV in faeces following each vaccine administration.
  • An immune response was detected in some horses, with BCoV antibodies observed in one horse after the first administration and two additional horses following the second administration.

Conclusions of the Study

  • The BCoV vaccine when administered to horses resulted in minimal virus shedding and produced an observable humoral response in 27% of the vaccinated animals.
  • The vaccine did cause some minor and self-limiting changes in faecal characteristics.
  • The study concluded the modified live BCoV vaccine to be safe to administer to horses via multiple routes with no major health compromises.

Cite This Article

APA
Prutton JSW, Barnum S, Pusterla N. (2019). Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination. Equine Vet Educ, 32(Suppl 11), 33-36. https://doi.org/10.1111/eve.13175

Publication

ISSN: 0957-7734
NlmUniqueID: 9885274
Country: England
Language: English
Volume: 32
Issue: Suppl 11
Pages: 33-36

Researcher Affiliations

Prutton, J S W
  • Department of Medicine and Epidemiology School of Veterinary Medicine University of California Davis California USA.
  • Present address: Liphook Equine Hospital Forest Mere Liphook Hampshire GU30 7JG UK.
Barnum, S
  • Department of Medicine and Epidemiology School of Veterinary Medicine University of California Davis California USA.
Pusterla, N
  • Department of Medicine and Epidemiology School of Veterinary Medicine University of California Davis California USA.

References

This article includes 17 references
  1. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.. Scand J Immunol 2004 Jan;59(1):1-15.
  2. Fielding CL, Higgins JK, Higgins JC, McIntosh S, Scott E, Giannitti F, Mete A, Pusterla N. Disease associated with equine coronavirus infection and high case fatality rate.. J Vet Intern Med 2015 Jan;29(1):307-10.
    pmc: PMC4858071pubmed: 25319406doi: 10.1111/jvim.12480google scholar: lookup
  3. Ghosh S, Taniguchi K, Aida S, Ganesh B, Kobayashi N. Whole genomic analyses of equine group A rotaviruses from Japan: evidence for bovine-to-equine interspecies transmission and reassortment events.. Vet Microbiol 2013 Oct 25;166(3-4):474-85.
    pubmed: 23938116doi: 10.1016/j.vetmic.2013.07.016google scholar: lookup
  4. Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, Holland R, Osterrieder N. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).. Vaccine 2006 Apr 24;24(17):3636-45.
    pubmed: 16513225doi: 10.1016/j.vaccine.2006.01.062google scholar: lookup
  5. Guy JS, Breslin JJ, Breuhaus B, Vivrette S, Smith LG. Characterization of a coronavirus isolated from a diarrheic foal.. J Clin Microbiol 2000 Dec;38(12):4523-6.
  6. Kollaritsch H, Rendi‐Wagner P. Principles of Immunization. In: Travel Medicine, 3rd edn., Eds: Keystone Jay S., Kozarsky Phyllis E., Freedman David O., Nothdruft Hans D. and Connor Bradley A., Elsevier, Philadelphia, PA. pp 67-76.
  7. Kooijman LJ, Mapes SM, Pusterla N. Development of an equine coronavirus-specific enzyme-linked immunosorbent assay to determine serologic responses in naturally infected horses.. J Vet Diagn Invest 2016 Jul;28(4):414-8.
    pubmed: 27216723doi: 10.1177/1040638716649643google scholar: lookup
  8. Mapes S, Rhodes DM, Wilson WD, Leutenegger CM, Pusterla N. Comparison of five real-time PCR assays for detecting virulence genes in isolates of Escherichia coli from septicaemic neonatal foals.. Vet Rec 2007 Nov 24;161(21):716-8.
    pubmed: 18037693doi: 10.1136/vr.161.21.716google scholar: lookup
  9. Miszczak F, Tesson V, Kin N, Dina J, Balasuriya UB, Pronost S, Vabret A. First detection of equine coronavirus (ECoV) in Europe.. Vet Microbiol 2014 Jun 25;171(1-2):206-9.
  10. Nemoto M, Kanno T, Bannai H, Tsujimura K, Yamanaka T, Kokado H. Antibody response to equine coronavirus in horses inoculated with a bovine coronavirus vaccine.. J Vet Med Sci 2017 Nov 17;79(11):1889-1891.
    pmc: PMC5709570pubmed: 28993568doi: 10.1292/jvms.17-0414google scholar: lookup
  11. Oue Y, Ishihara R, Edamatsu H, Morita Y, Yoshida M, Yoshima M, Hatama S, Murakami K, Kanno T. Isolation of an equine coronavirus from adult horses with pyrogenic and enteric disease and its antigenic and genomic characterization in comparison with the NC99 strain.. Vet Microbiol 2011 May 12;150(1-2):41-8.
  12. Oue Y, Morita Y, Kondo T, Nemoto M. Epidemic of equine coronavirus at Obihiro Racecourse, Hokkaido, Japan in 2012.. J Vet Med Sci 2013;75(9):1261-5.
    pubmed: 23648375doi: 10.1292/jvms.13-0056google scholar: lookup
  13. Pusterla N, Hilton H, Wattanaphansak S, Collier JR, Mapes SM, Stenbom RM, Gebhart C. Evaluation of the humoral immune response and fecal shedding in weanling foals following oral and intra-rectal administration of an avirulent live vaccine of Lawsonia intracellularis.. Vet J 2009 Dec;182(3):458-62.
    pubmed: 18835201doi: 10.1016/j.tvjl.2008.08.016google scholar: lookup
  14. Pusterla N, Mapes S, Wademan C, White A, Ball R, Sapp K, Burns P, Ormond C, Butterworth K, Bartol J, Magdesian KG. Emerging outbreaks associated with equine coronavirus in adult horses.. Vet Microbiol 2013 Feb 22;162(1):228-31.
  15. Thurber ET, Bass EP, Beckenhauer WH. Field trial evaluation of a reo-coronavirus calf diarrhea vaccine.. Can J Comp Med 1977 Apr;41(2):131-6.
    pmc: PMC1277709pubmed: 193622
  16. Waltner-Toews D, Martin SW, Meek AH, McMillan I, Crouch CF. A field trial to evaluate the efficacy of a combined rotavirus-coronavirus/Escherichia coli vaccine in dairy cattle.. Can J Comp Med 1985 Jan;49(1):1-9.
    pmc: PMC1236108pubmed: 2985213
  17. Woo PC, Lau SK, Huang Y, Yuen KY. Coronavirus diversity, phylogeny and interspecies jumping.. Exp Biol Med (Maywood) 2009 Oct;234(10):1117-27.
    pubmed: 19546349doi: 10.3181/0903-mr-94google scholar: lookup

Citations

This article has been cited 1 times.
  1. Mashin VV, Sergeev AN, Martynova NN, Sergeev AA, Lys'ko KA, Raikov AO, Kataeva VV, Zagidullin NV. Viral Safety Issues in the Production and Manufacturing of Human Immunoglobulin Preparations from Equine Plasma/Serum. Pharm Chem J 2022;56(4):532-537.
    doi: 10.1007/s11094-022-02675-2pubmed: 35845147google scholar: lookup